PSP Research’s United Therapeutics UTHR Stock Holding History

PSP Research’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-350	Closed	-$208K	–	89
2026 Q1	$208K	Sell	350 -730	-68%	-$364K	0.15%	71
2025 Q4	$526K	Buy	+1,080	New	+$503K	0.46%	54

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

PSP Research's UTHR Position: Q2 2026 in Review

PSP Research sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 350 shares — an estimated $208K sold.

PSP Research first reported a position in UTHR in Q4 2025 and held it in 2 quarters. The position peaked at $526K in Q4 2025. 877 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

PSP Research reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
PSP Research sold 350 United Therapeutics shares in Q2 2026, an estimated $208K.
PSP Research first reported a position in United Therapeutics in Q4 2025 and held it in 2 quarters.
PSP Research's United Therapeutics position peaked at $526K in Q4 2025.
877 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.